Vitamin D Receptor Genotype, Vitamin D3 Supplementation, and Risk of Colorectal Adenomas -A Randomized Clinical Trial
JAMA Oncol. 2017;3(5):628-635. doi:10.1001/jamaoncol.2016.5917
Elizabeth L. Barry, PhD1; Janet L. Peacock, PhD2; Judy R. Rees, BM, Bch, PhD1; et al Roberd M. Bostick, MD3; Douglas J. Robertson, MD4; Robert S. Bresalier, MD5; John A. Baron, MD1,6
- After 30 years it still appears that vitamin D deals with colorectal cancer – Oct 2012
- Colorectal cancer 60 percent less likely if have more than 50 ng of vitamin D (vs 5 ng) – meta-analysis April 2017
- Colorectal cancer 60 percent less likely: high vs low Vitamin D level – meta-analysis Dec 2016
- Colon cancer 30 percent more likely if problems with Vitamin D genes CYP24A1 or CYP27B1 – Nov 2015
- Overview Cancer-Colon and vitamin D includes the following chart
- Question Do common variants in vitamin D and calcium pathway genes modify effects of vitamin D3 or calcium supplementation on risk of colorectal adenomas?
- Findings In a randomized clinical trial, the effect of vitamin D3 supplementation on advanced adenomas (but not adenoma risk overall) significantly varied according to vitamin D receptor genotypes. Among individuals with the rs7968585 AA genotype, vitamin D supplementation reduced risk by 64%, while among those with 1 or 2 G alleles, risk was increased by 41%.
- Meaning This study provides some clarity on who may benefit from vitamin D3 supplementation for preventing advanced colorectal adenomas based on vitamin D receptor genotype.
Importance Despite epidemiological and preclinical evidence suggesting that vitamin D and calcium inhibit colorectal carcinogenesis, daily supplementation with these nutrients for 3 to 5 years was not found to significantly reduce the risk of recurrent colorectal adenomas in a recent randomized clinical trial.
Objective To investigate whether common variants in 7 vitamin D and calcium pathway genes (VDR, GC, DHCR7, CYP2R1, CYP27B1, CYP24A1, and CASR) modify the effects of vitamin D3 or calcium supplementation on colorectal adenoma recurrence.
Design, Setting, and Participants We examined 41 candidate single-nucleotide polymorphisms (SNPs) in 2259 participants in a randomized, double-blind, placebo-controlled trial conducted at 11 clinical centers in the United States. Eligibility criteria included a recently diagnosed adenoma and no remaining colorectal polyps after complete colonoscopy. The study’s treatment phase ended on August 31, 2013, and the analysis for the present study took place from July 28, 2014, to October 19, 2016.
Interventions Daily oral supplementation with vitamin D3 1000 IU) or calcium carbonate (1200 mg elemental calcium) or both or neither.
Main Outcomes and Measures The outcomes assessed were the occurrence of 1 or more adenomas or advanced adenomas (estimated diameter, ≥1 cm; or with villous histologic findings, high-grade dysplasia, or cancer) during follow-up. Treatment effects and genotype associations and interactions were estimated as adjusted risk ratios (RRs) and 95% confidence intervals (CIs). The effective number of independent SNPs was calculated to correct for multiple testing.
Results Among the 2259 participants randomized, 1702 were non-Hispanic whites who completed the trial and had genotype data for analysis (1101 men; mean [SD] age 58.1 [6.8] years). The effect of vitamin D3 supplementation on advanced adenomas, but not on adenoma risk overall, significantly varied according to genotype at 2 VDR SNPs (rs7968585 and rs731236) in linkage disequilibrium (D′ = 0.98; r2 = 0.6). For rs7968585, among individuals with the AA genotype (26%), vitamin D3 supplementation reduced risk by 64% (RR, 0.36; 95% CI, 0.19-0.69; P = .002; absolute risk decreased from 14.4% to 5.1%). Among individuals with 1 or 2 G alleles (74%), vitamin D3 supplementation increased risk by 41% (RR, 1.41; 95% CI, 0.99-2.00; P = .05; absolute risk increased from 7.7% to 11.1%; P < .001 for interaction). There were no significant interactions of genotypes with calcium supplementation.
Conclusions and Relevance Our findings suggest that benefits from vitamin D3 supplementation for the prevention of advanced colorectal adenomas may vary according to vitamin D receptor genotype.
Trial Registration clinicaltrials.gov Identifier: NCT00153816